Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis
- PMID: 29721816
- DOI: 10.1007/s40257-018-0356-7
Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis
Abstract
Background: There is little consensus regarding the prevalence and distribution of underlying systemic diseases among patients with pyoderma gangrenosum.
Objective: The objective of this study was to synthesize existing data on the prevalence of associated systemic diseases in patients with pyoderma gangrenosum.
Methods: We performed a systematic review and meta-analysis of observational studies in MEDLINE, EMBASE, and Scopus (1823-2017). The quality of evidence was assessed using a modified Newcastle-Ottawa Scale. A meta-analysis was performed using random-effects models to estimate pooled prevalence rates with 95% confidence intervals.
Results: Twenty-one eligible studies comprising 2611 patients with pyoderma gangrenosum were included in the quantitative synthesis. The overall random-effects pooled prevalence of associated systemic diseases was 56.8% (95% confidence interval 45.5-67.4). The leading underlying disease was inflammatory bowel disease (17.6%; 95% confidence interval 13.0-22.7), followed by arthritis (12.8%; 95% confidence interval 9.2-16.9), hematological malignancies (8.9%; 95% confidence interval 6.5-11.6), and solid malignancies (7.4%; 95% confidence interval 5.8-9.1). In 16.3% (95% confidence interval 7.7-27.1) of cases, the onset of pyoderma gangrenosum was attributed to the pathergy phenomenon.
Conclusions: More than half of patients with pyoderma gangrenosum present with a relevant underlying disease. Inflammatory bowel disease and arthritis are the most frequently associated diseases. Relative to the reported literature, the pooled prevalence of arthritis and hematological malignancies is lower, while the pooled prevalence of solid malignancies is higher. Owing to the high level of heterogeneity among most of the comparisons, results should be interpreted with caution.
Similar articles
-
Pediatric pyoderma gangrenosum: a systematic review and update.Int J Dermatol. 2017 May;56(5):486-495. doi: 10.1111/ijd.13584. Epub 2017 Feb 23. Int J Dermatol. 2017. PMID: 28233293
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
The role of negative pressure wound therapy (NPWT) on the treatment of pyoderma gangrenosum: A systematic review and personal experience.Wound Repair Regen. 2021 May;29(3):486-494. doi: 10.1111/wrr.12910. Epub 2021 Mar 27. Wound Repair Regen. 2021. PMID: 33772964
-
Gestational weight gain below instead of within the guidelines per class of maternal obesity: a systematic review and meta-analysis of obstetrical and neonatal outcomes.Am J Obstet Gynecol MFM. 2022 Sep;4(5):100682. doi: 10.1016/j.ajogmf.2022.100682. Epub 2022 Jun 18. Am J Obstet Gynecol MFM. 2022. PMID: 35728780
-
Oxycodone for cancer-related pain.Cochrane Database Syst Rev. 2022 Jun 9;6(6):CD003870. doi: 10.1002/14651858.CD003870.pub7. Cochrane Database Syst Rev. 2022. PMID: 35679121 Free PMC article.
Cited by
-
Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations.Front Immunol. 2023 Oct 26;14:1234535. doi: 10.3389/fimmu.2023.1234535. eCollection 2023. Front Immunol. 2023. PMID: 37954590 Free PMC article. Review.
-
Pyoderma gangrenosum.Nat Rev Dis Primers. 2020 Oct 8;6(1):81. doi: 10.1038/s41572-020-0213-x. Nat Rev Dis Primers. 2020. PMID: 33033263 Review.
-
Concurrent Scleredema and Pyoderma Gangrenosum: Case Report and Review of Comorbid Conditions.Cureus. 2020 Dec 20;12(12):e12188. doi: 10.7759/cureus.12188. Cureus. 2020. PMID: 33489598 Free PMC article.
-
Pyoderma Gangrenosum: A Retrospective Case Series of 44 Patients.Dermatol Pract Concept. 2024 Oct 30;14(4):e2024265. doi: 10.5826/dpc.1404a265. Dermatol Pract Concept. 2024. PMID: 39652952 Free PMC article.
-
Treatment of systemic sclerosis complicated with pyoderma gangrenosum with adalimumab: A case report of a rare disease.Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241300137. doi: 10.1177/03946320241300137. Int J Immunopathol Pharmacol. 2024. PMID: 39584543 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources